Drug Topics
FEBRUARY 7, 2024
Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).
Pharmacy Times
FEBRUARY 7, 2024
The 23-valent pneumococcal polysaccharide vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised, but the events were low.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 7, 2024
David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence. At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the dr
Pharmacy Times
FEBRUARY 7, 2024
Investigators also found that the mortality rates for cardiovascular disease from 2020 to 2022 reversed the improvements of reduced mortalities in the preceding decades.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 7, 2024
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers. But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI?
Pharmacy Times
FEBRUARY 7, 2024
The investigators identified 4 prognostic factors with high predictive ability and supported by moderate to high strength evidence beyond what is already available for cardiovascular disease.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
FEBRUARY 7, 2024
Amazon is eliminating a "few hundred roles" across One Medical and Amazon Pharmacy, the company confirmed Tuesday. | Amazon is eliminating a "few hundred roles" across One Medical and Amazon Pharmacy, the company confirmed Tuesday.
STAT
FEBRUARY 7, 2024
Fatigue leads the list of persistent problems experienced by people with long Covid — which is why patients have pushed back against treatment approaches that endorse escalating levels of exercise for a condition that researchers are still trying to understand. They fear post-exertional malaise, the debilitating price to be paid for pushing their bodies too hard.
Drug Topics
FEBRUARY 7, 2024
In terms of geographic representation, nonmetropolitan counties, the West, and the South had higher excess deaths than reported COVID-19 deaths.
STAT
FEBRUARY 7, 2024
Maria Curotto de Lafaille’s lab was trying to make human plasma cells in a dish. These weren’t just run-of-the-mill cells, though. The team was vying for something specific: plasma cells that churn out immunoglobulin E (IgE), the antibody that drives allergic reactions. It was the mid-2010s, and from a research bench at the Immunology Network of A*STAR in Singapore, one of Lafaille’s postdocs, Sriram Narayanan, was plopping donated human B cells into a culture dish wit
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
FEBRUARY 7, 2024
By involving pharmacists, patients can see improved medication adherence, improved outcomes, and, as a result, reduced health care costs
Fierce Healthcare
FEBRUARY 7, 2024
Three months following the merger of Virgin Pulse and benefits administrator HealthComp, the combined company has rebranded as Personify Health with its sights set on revamping the patient experien | Personify Health introduced what it calls a personalized health platform that combines HealthComp's health plan administration capabilities with Virgin Pulse's holistic wellbeing solutions and comprehensive health navigation.
pharmaphorum
FEBRUARY 7, 2024
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.
STAT
FEBRUARY 7, 2024
Amid ongoing concern over opioid addiction, a university in Florida has been criticized for allowing a lecture that conveyed “false and misleading” information about the use of the prescription painkillers by a local physician who, in years past, had ties to opioid makers. At issue was a lecture that was given last October at Nova Southeastern University in Fort Lauderdale, Fla., by Martin Hale, an orthopedic surgeon, to first-year medical students about managing pain.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
FEBRUARY 7, 2024
As the pandemic recedes and the global economy stabilises, are there promising signs for the biotech industry's financial outlook in 2024? Learn more about the potential for recovery, reducing bankruptcies, and attracting investors.
STAT
FEBRUARY 7, 2024
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences. Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.
Fierce Pharma
FEBRUARY 7, 2024
Despite markedly slower cell therapy growth from the third to the fourth quarter of 2023—and a recent setback for Trodelvy—historically HIV-focused Gilead Sciences is not discouraged amid its | Despite a tame level of fourth-quarter growth, recent advances should drive long-term cell therapy sustainability, Gilead execs said. Overall, the company is pushing to generate 30% of its revenues from oncology by 2030.
STAT
FEBRUARY 7, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.
Fierce Healthcare
FEBRUARY 7, 2024
Montefiore Medical Center has agreed to a $4.75 million settlement over data security failures federal officials uncovered when investigating an employee who had sold patient information to crimina | Federal officials investigated the New York City-based health system after an incident in which an employee's inappropriate access and sale of patient data wasn't detected for more than a year.
The FDA Law Blog
FEBRUARY 7, 2024
By John A. Gilbert — Last week, DEA and DOJ announced a $59 million civil penalty settlement with eBay related to the failure to comply with Controlled Substances Act (CSA) requirements for identifying purchasers, maintaining records, and filing reports of individuals selling/purchasing pill presses and encapsulating machines. As stated in the press release , this was the fourth largest civil penalty settlement under the CSA and, ironically, did not involve the sale or distribution of any contr
pharmaphorum
FEBRUARY 7, 2024
Stay updated on the latest clinical trials happening from January 15th to January 19th, 2024. Explore trials by ExeVir, NurixTx, Synendos Therapeutics, and Oxford BioTx.
STAT
FEBRUARY 7, 2024
As leaders across federal agencies swiftly advance regulations for AI in health care, one proposal now seems too big to fail. That proposal is for the implementation of AI assurance laboratories — places where AI model developers can develop and test AI models according to standard criteria that would be defined with regulators.
pharmaphorum
FEBRUARY 7, 2024
In this interview, Simon Arkell, co-founder and CEO of Ryght, discusses his vision whilst at JP Morgan 2024 and how generative AI is transforming the industry.
Fierce Pharma
FEBRUARY 7, 2024
Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s disease med appears to be moving | While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid-busting antibody as of Jan. 26, Eisai explained in a third-quarter earnings presentation.
Pharmacy Times
FEBRUARY 7, 2024
In November 2023, the FDA announced an investigation of CAR T-cell therapy based on several reported secondary T-cell malignancies.
STAT
FEBRUARY 7, 2024
Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, if you must. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today is maple bourbon — and get started.
Drug Store News
FEBRUARY 7, 2024
Every year, HRG conducts a review of the new health, beauty, and wellness products released to identify trends and shifts in the market.
pharmaphorum
FEBRUARY 7, 2024
GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there but was withdrawn from sale after it failed a confirmatory trial.
Fierce Pharma
FEBRUARY 7, 2024
As part of the acquisition of manufacturing giant Catalent, Novo Nordisk will fork over $11 billion for three of the CDMO’s plants. | While Catalent’s Bloomington, Indiana, site is no stranger to FDA reprimands, its latest write-up is notable given that the site forms part of the $16.5 billion deal Novo Holdings struck to acquire Catalent earlier this week.
Drug Store News
FEBRUARY 7, 2024
Featuring puffed-up and larger-than-life squares that are filled with a vanilla crème, the Loaded cereal lineup will include Cinnamon Toast Crunch, Trix and Cocoa Puffs.
Fierce Pharma
FEBRUARY 7, 2024
After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepez | After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepezza—an instant blockbuster that saw a perplexing slide in just its third full year on the market.
The Checkup by Singlecare
FEBRUARY 7, 2024
Feeling unsteady or off-balance can be scary, especially if the sensation comes on suddenly. If you’ve been diagnosed with diabetes mellitus , dizziness may be an uncomfortably familiar experience. That’s because diabetes can cause blood sugar swings and dehydration—common causes of dizziness or lightheadedness. Untreated or poorly managed diabetes can also lead to complications such as vestibular dysfunction, which makes you feel unsteady on your feet.
pharmaphorum
FEBRUARY 7, 2024
Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.
Fierce Healthcare
FEBRUARY 7, 2024
Patients living in poor neighborhoods are more likely to have worse postsurgical outcomes even if they’ve got insurance coverage, according to a
Expert insights. Personalized for you.
201 
Let's personalize your content